Second-generation Gc-MAF is produced using a new patented process which was developed here in Japan by Saisei Mirai in collaboration with researchers from the University of Tokushima who have been studying GcMAF for over 20 years. Our GcMAF is made in our sterile cell processing facility using this new and improved 2nd generation method which is 10-15 times more concentrated and is more active and stable than other GcMAF currently available. More importantly, this much higher concentration GcMAF has been clinically demonstrated to be largely free of any side effects in the great majority of patients and is much more stable as it is resistant to oxidation. Only low grade fever or eczema have been observed in about 1 out of 100 patients using GcMAF but these were short-term effects.
- 0.5 ml of High-Dose GcMAF is approximately 1500 ng GcMAF
- Gc-MAF is a natural immunotherapy product. Variation in GcMAF concentration is due to normal variation between serum samples. In the same way that lymphocytes or natural killer cells vary in number between people at any given time, so will the amount of GcMAF that can be produced from serum.
- Our GcMAF is produced under aseptic conditions in a specialized facility and sterile filtration is used in the production of all product.
- Our new 2nd generation Gc-MAF has been safely used in hundreds of patients in our clinic in Japan, since April 2011. Treatment in our clinic has been by Intramuscular (IM), Subcutaneous (SC) and Intramural (IT) injection.